Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 166

1.

Peptides and proteins in plasma and cerebrospinal fluid as biomarkers for the prediction, diagnosis, and monitoring of therapeutic efficacy of Alzheimer's disease.

Aluise CD, Sowell RA, Butterfield DA.

Biochim Biophys Acta. 2008 Oct;1782(10):549-58. doi: 10.1016/j.bbadis.2008.07.008. Epub 2008 Aug 7. Review.

2.

Plasma and cerebrospinal fluid amyloid beta for the diagnosis of Alzheimer's disease dementia and other dementias in people with mild cognitive impairment (MCI).

Ritchie C, Smailagic N, Noel-Storr AH, Takwoingi Y, Flicker L, Mason SE, McShane R.

Cochrane Database Syst Rev. 2014 Jun 10;(6):CD008782. doi: 10.1002/14651858.CD008782.pub4. Review.

PMID:
24913723
3.

Laboratory biomarkers in Alzheimer's disease.

Steinerman JR, Honig LS.

Curr Neurol Neurosci Rep. 2007 Sep;7(5):381-7. Review.

PMID:
17764627
4.

An integrated workflow for multiplex CSF proteomics and peptidomics-identification of candidate cerebrospinal fluid biomarkers of Alzheimer's disease.

Hölttä M, Minthon L, Hansson O, Holmén-Larsson J, Pike I, Ward M, Kuhn K, Rüetschi U, Zetterberg H, Blennow K, Gobom J.

J Proteome Res. 2015 Feb 6;14(2):654-63. doi: 10.1021/pr501076j. Epub 2014 Dec 22.

PMID:
25490617
5.

YKL-40: a novel prognostic fluid biomarker for preclinical Alzheimer's disease.

Craig-Schapiro R, Perrin RJ, Roe CM, Xiong C, Carter D, Cairns NJ, Mintun MA, Peskind ER, Li G, Galasko DR, Clark CM, Quinn JF, D'Angelo G, Malone JP, Townsend RR, Morris JC, Fagan AM, Holtzman DM.

Biol Psychiatry. 2010 Nov 15;68(10):903-12. doi: 10.1016/j.biopsych.2010.08.025. Erratum in: Biol Psychiatry. 2011 Feb 15;69(4):389.

6.

Clinical indications for analysis of Alzheimer's disease CSF biomarkers.

Engelborghs S.

Rev Neurol (Paris). 2013 Oct;169(10):709-14. doi: 10.1016/j.neurol.2013.07.024. Epub 2013 Sep 6. Review.

PMID:
24016466
7.

Biomarkers of Alzheimer's disease in body fluids.

Zheng Y, He J, Hong T.

Sci China Life Sci. 2010 Apr;53(4):490-6. doi: 10.1007/s11427-010-0081-9. Epub 2010 May 7. Review.

PMID:
20596916
8.

Simultaneous analysis of cerebrospinal fluid biomarkers using microsphere-based xMAP multiplex technology for early detection of Alzheimer's disease.

Kang JH, Vanderstichele H, Trojanowski JQ, Shaw LM.

Methods. 2012 Apr;56(4):484-93. doi: 10.1016/j.ymeth.2012.03.023. Epub 2012 Apr 6. Review.

PMID:
22503777
9.

Multiplexing Biomarker Methods, Proteomics and Considerations for Alzheimer's Disease.

Robinson RA, Amin B, Guest PC.

Adv Exp Med Biol. 2017;974:21-48. doi: 10.1007/978-3-319-52479-5_2. Review.

PMID:
28353223
10.

Identifying and validating biomarkers for Alzheimer's disease.

Humpel C.

Trends Biotechnol. 2011 Jan;29(1):26-32. doi: 10.1016/j.tibtech.2010.09.007. Epub 2010 Oct 23. Review.

11.

Identification and validation of novel cerebrospinal fluid biomarkers for staging early Alzheimer's disease.

Perrin RJ, Craig-Schapiro R, Malone JP, Shah AR, Gilmore P, Davis AE, Roe CM, Peskind ER, Li G, Galasko DR, Clark CM, Quinn JF, Kaye JA, Morris JC, Holtzman DM, Townsend RR, Fagan AM.

PLoS One. 2011 Jan 12;6(1):e16032. doi: 10.1371/journal.pone.0016032.

12.

Apolipoprotein E genotype and the diagnostic accuracy of cerebrospinal fluid biomarkers for Alzheimer disease.

Lautner R, Palmqvist S, Mattsson N, Andreasson U, Wallin A, Pålsson E, Jakobsson J, Herukka SK, Owenius R, Olsson B, Hampel H, Rujescu D, Ewers M, Landén M, Minthon L, Blennow K, Zetterberg H, Hansson O; Alzheimer’s Disease Neuroimaging Initiative.

JAMA Psychiatry. 2014 Oct;71(10):1183-91. doi: 10.1001/jamapsychiatry.2014.1060.

PMID:
25162367
13.

Cost-effectiveness of the use of biomarkers in cerebrospinal fluid for Alzheimer's disease.

Valcárcel-Nazco C, Perestelo-Pérez L, Molinuevo JL, Mar J, Castilla I, Serrano-Aguilar P.

J Alzheimers Dis. 2014;42(3):777-88. doi: 10.3233/JAD-132216.

PMID:
24916543
14.

[Use of cerebrospinal fluid (CSF) biomarkers for Alzheimer's type dementia: diagnosis in mild cognitive impairment].

Verhey FR, Visser PJ.

Ned Tijdschr Geneeskd. 2013;157(11):A5596. Review. Dutch.

PMID:
23484512
15.

A candidate plasma protein classifier to identify Alzheimer's disease.

Zhao X, Lejnine S, Spond J, Zhang C, Ramaraj TC, Holder DJ, Dai H, Weiner R, Laterza OF.

J Alzheimers Dis. 2015;43(2):549-63. doi: 10.3233/JAD-141149.

PMID:
25114072
16.

Peptide fingerprinting of Alzheimer's disease in cerebrospinal fluid: identification and prospective evaluation of new synaptic biomarkers.

Jahn H, Wittke S, Zürbig P, Raedler TJ, Arlt S, Kellmann M, Mullen W, Eichenlaub M, Mischak H, Wiedemann K.

PLoS One. 2011;6(10):e26540. doi: 10.1371/journal.pone.0026540. Epub 2011 Oct 26.

17.

Cerebrospinal fluid cortisol and clinical disease progression in MCI and dementia of Alzheimer's type.

Popp J, Wolfsgruber S, Heuser I, Peters O, Hüll M, Schröder J, Möller HJ, Lewczuk P, Schneider A, Jahn H, Luckhaus C, Perneczky R, Frölich L, Wagner M, Maier W, Wiltfang J, Kornhuber J, Jessen F.

Neurobiol Aging. 2015 Feb;36(2):601-7. doi: 10.1016/j.neurobiolaging.2014.10.031. Epub 2014 Oct 31.

PMID:
25435336
18.

Biomarkers in Alzheimer's disease analysis by mass spectrometry-based proteomics.

Liu Y, Qing H, Deng Y.

Int J Mol Sci. 2014 May 6;15(5):7865-82. doi: 10.3390/ijms15057865. Review.

19.

Core candidate neurochemical and imaging biomarkers of Alzheimer's disease.

Hampel H, Bürger K, Teipel SJ, Bokde AL, Zetterberg H, Blennow K.

Alzheimers Dement. 2008 Jan;4(1):38-48. doi: 10.1016/j.jalz.2007.08.006. Epub 2007 Dec 21. Review.

PMID:
18631949
20.

Assessment of cerebrospinal fluid (CSF) beta-amyloid (1-42), phosphorylated tau (ptau-181) and total Tau protein in patients with Alzheimer's disease (AD) and other dementia at Siriraj Hospital, Thailand.

Thaweepoksomboon J, Senanarong V, Poungvarin N, Chakorn T, Siwasariyanon N, Washirutmangkur L, Udompunthuruk S.

J Med Assoc Thai. 2011 Feb;94 Suppl 1:S77-83.

PMID:
21721431

Supplemental Content

Support Center